… Mean survival in the naïve antifibrotic … and survival, we found no differences between
definitive or probable UIP radiological patterns, both on patients under nintedanib and pirfenidone (…

… , the average survival of patients with IPF + PH was less than 3 years, while in our study (where
all PFI patients were in therapy with pirfenidone or nintedanib), even patients with severe …

… We included patients with IPF who initiated treatment with nintedanib or pirfenidone from
August … Patients were classified as having ‘advanced IPF’ if their FVC was less than 50% of …

… Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the treatment of patients
with … This study aimed to compare pirfenidone and nintedanib-treated patients regarding all-…

… patients permanently discontinued antifibrotic treatment due to side effects (14 with pirfenidone,
7 with nintedanib… a similar effectiveness between pirfenidone and nintedanib in terms of …

… in patients treated with nintedanib or pirfenidone and explored their effect on patient survival
in … However, the survival of patients treated with nintedanib and pirfenidone appears to be …

… have showed better survival in patients with IPF receiving … -world survival data from large
unselected European patient … rates in patients with IPF receiving pirfenidone or nintedanib, …

… First, it was not a randomized controlled trial; however, at this time, we are not aware of any
ongoing study enrolling three arms of patients (placebo, pirfenidone, and nintedanib), so it …

… Pirfenidone and Nintedanib in a population of patients followed at our hospital last year.
The clinical and functional characteristics of IPF patients treated with Pirfenidone or Nintedanib …

… (21) We offered the option of switching to nintedanib to subjects who discontinued
pirfenidone due to ADRs, did not tolerate the full-dose, or had disease progression on …